Indications
Prevention of meningitis due to meningococcus A in countries of the African meningitis belt
PDF page 524
Loading InternPractice…
Drug reference
Prevention of meningitis due to meningococcus A in countries of the African meningitis belt
PDF page 524
Do not administer to patients with history of an allergic reaction to a previous injection of meningococcal vaccine. Vaccination should be postponed in the event of severe acute febrile illness (minor infections are not contra-indications). May cause: mild local reaction, mild fever. Do not mix with other vaccines in the same syringe (inactivation of vaccines). If administered simultaneously with other vaccines, use different syringes and injection sites. Pregnancy: no contra-indication Breast-feeding: no contra-indication
PDF page 524
Inactivated bacterial vaccine, conjugated (Neisseria meningitidis group A) Powder for injection, to be dissolved with the entire vial of the diluent supplied by the manufacturer Vials of 10 doses of: 5 micrograms of meningococcal A antigen per 0.5 ml dose for children aged 3 to 24 months 10 micrograms of meningococcal A antigen per 0.5 ml dose for children from 1 year and adults up to 29 years For deep IM injection, into the anterolateral part of the thigh in children < 2 years or into the deltoid muscle in children ≥ 2 years and adults
PDF page 524
Child 3 to < 9 months: 2 doses of 0.5 ml, to be administered at least 8 weeks apart Child 9 months and over: 0.5 ml single dose Adult: 0.5 ml single dose
PDF page 524
Immunity lasts at least 27 months. The WHO recommends this vaccine for routine vaccination in children aged 9 to 18 months, in catch-up or periodic campaigns in children from 1 year and in mass vaccination campaigns during outbreaks due to meningococcus A in children from 1 year and adults up to 29 years.
PDF page 524
– Do not freeze. Powder: between 2 °C and 8 °C. Diluent: a cold chain is not required for storage. However, at least 12 hours before reconstitution of the vaccine, the diluent must be refrigerated between 2 °C and 8 °C so that the diluent and lyophilised powder are at the same temperature: a temperature difference during reconstitution may reduce vaccine efficacy. Reconstituted vaccine: up to 40 °C for 6 hours maximum. Controlled temperature chain (CTC): during mass vaccination campaigns only, the 10 microgram vaccine can be stored in temperatures of up to 40 °C for a period of 4 days maximum. Any vaccine removed from the cold chain and not used within 4 days or exposed to temperatures > 40 °C must be discarded.
PDF page 525
0.5 ml single dose
PDF page 524